Sildenafil in the treatment of pulmonary hypertension

Christopher F Barnett1,2
Roberto F Machado1,2

1Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA; 2Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Abstract: The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-selective vasodilators to drugs that specifically target pulmonary vasodilation, endothelial function, and vascular remodeling. Sildenafil is a phosphodiesterase type 5 inhibitor that has an expanding role in the treatment of pulmonary hypertension. Case series and small studies, as well as the first large randomized controlled trial, have demonstrated the safety and efficacy of sildenafil in improving mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index, and exercise tolerance in pulmonary arterial hypertension. It may be useful in adults, children, and neonates after cardiac surgery, with left heart failure, in fibrotic pulmonary disease, high altitude exposure, and thromboembolic disease, and in combination with other therapies for pulmonary hypertension, such as inhaled iloprost. The oral formulation and favorable adverse effect profile make sildenafil an attractive alternative in the treatment of selected patients with pulmonary hypertension.

Keywords: sildenafil, phosphodiesterase inhibitor, pulmonary hypertension, right heart failure

Introduction

The development of sildenafil began in 1986 when chemists at Pfizer searching for a compound to treat hypertension chose to target augmentation of the renal tubular activity of atrial natriuretic peptide through its second messenger cyclic guanosine monophosphate (cGMP) and the phosphodiesterase (PDE) family of enzymes (Kling 1998). Test compounds were shown to antagonize the activity of PDE 5, resulting in vasodilation and platelet inhibition, turning their focus to treatment of angina. Trials in angina were disappointing but some patients reported the surprising and unexpected side-effect of penile erections (Morales et al 1998), leading to its development as a treatment for erectile dysfunction. As understanding of the mechanism of sildenafil grew, a role in the treatment of pulmonary hypertension (PH) was postulated, eventually leading to the recent Super-1 trial and FDA approval for this indication. Sildenafil is administered orally, is well tolerated with few drug interactions, and does not require intensive monitoring, making it an attractive alternative to other drugs for the treatment of PH. In this article, we review the growing role of sildenafil in the treatment of PH.

PH pathogenesis and clinical course

Pulmonary hypertension is a general term for a disease process resulting in a progressive increase in the mean pulmonary artery pressure (mPAP) (mPAP ≥25 mmHg at rest or ≥30 mmHg with exercise) (Barst et al 2004). According to the World Health Organization Revised Clinical Classification of Venice (Simonneau et al 2004), pulmonary arterial hypertension (PAH) is a specific subtype of PH with a pulmonary capillary wedge pressure (PCWP) ≤15 mmHg and by pulmonary vascular resistance (PVR) >3 wood units. PAH can be idiopathic, familial, or secondary to a variety of conditions such as connective tissue disease, hemoglobinopathies, or HIV infection (Table 1).
Endothelial dysfunction resulting from an imbalance of endogenous vasoconstrictors (eg, endothelin-1) and vasodilators (eg, nitric oxide [NO], prostacyclin) is thought to lead to vascular constriction, in situ thrombosis, and progressive remodeling of the pulmonary arteries (Pietra et al. 1989; Rubin 1997). Vascular remodeling in PAH is characterized by distal pulmonary arterial smooth muscle cell hypertrophy and proliferation with subsequent luminal narrowing and development of plexiform lesions. Regardless of the etiology, the pathologic appearance is remarkably similar, suggesting an underlying, common disease pathway (Galiè et al. 1998).

Patients with PH often present with signs and symptoms of right heart failure. Diagnostic evaluation includes a search for any underlying diseases followed by right heart catheterization for the measurement of mPAP, PCWP, and PVR, and performance of vasodilator testing. The 6 minute walk test is performed at baseline and on follow up to track exercise capacity and assess disease severity (Miyamoto et al. 2000; McLaughlin et al. 2002; Hoeper et al. 2004).

Therapies for PH

Prior to the advent of vasodilator therapy, progressive right-sided heart failure frequently lead to death within 2–3 years (D’Alonzo et al. 1991). Calcium channel blockers were the first drugs shown to benefit patients with idiopathic PAH (Rich et al. 1992) and remain first-line therapy in the few patients who respond during vasodilator testing (Sitbon et al. 2005). Based on autopsy findings of frequent undetected pulmonary thrombi (Fuster et al. 1984) and a small retrospective series showing increased transplant-free survival in anticoagulated patients, treatment with warfarin has also become a part of standard therapy. The use of diuretics and digoxin can help relieve symptoms of right heart failure.

In 1996, intravenous epoprostenol was shown in a randomized controlled trial to improve exercise tolerance, hemodynamics, and survival in PAH (Barst et al. 1996). Prostacyclin and other prostanoids are administered by continuous intravenous or subcutaneous infusion, inhalation, or orally. Treatment may be complicated by systemic

### Table 1 Revised clinical classification of pulmonary hypertension

<table>
<thead>
<tr>
<th>Category</th>
<th>Subcategory</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Pulmonary arterial hypertension (PAH)</td>
<td>1.1 Idiopathic (IPAH)</td>
</tr>
<tr>
<td>1. Pulmonary arterial hypertension (PAH)</td>
<td>1.2 Familial (FPAH)</td>
</tr>
<tr>
<td>1. Pulmonary arterial hypertension (PAH)</td>
<td>1.3 Associated with (APAH):</td>
</tr>
<tr>
<td>1.3.1 Collagen vascular disease</td>
<td></td>
</tr>
<tr>
<td>1.3.2 Congenital systemic-to-pulmonary shunts</td>
<td></td>
</tr>
<tr>
<td>1.3.3 Portal hypertension</td>
<td></td>
</tr>
<tr>
<td>1.3.4 HIV infection</td>
<td></td>
</tr>
<tr>
<td>1.3.5 Drugs and toxins</td>
<td></td>
</tr>
<tr>
<td>1.3.6 Other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy)</td>
<td></td>
</tr>
<tr>
<td>1.4 Associated with significant venous or capillary involvement</td>
<td></td>
</tr>
<tr>
<td>1.4.1 Pulmonary veno-occlusive disease (PVOD)</td>
<td></td>
</tr>
<tr>
<td>1.4.2 Pulmonary capillary hemangiomatosis (PCH)</td>
<td></td>
</tr>
<tr>
<td>1.5 Persistent pulmonary hypertension of the newborn</td>
<td></td>
</tr>
<tr>
<td>2. Pulmonary hypertension (PH) with left heart disease</td>
<td>2.1 Left-sided atrial or ventricular heart disease</td>
</tr>
<tr>
<td>2. Pulmonary hypertension (PH) with left heart disease</td>
<td>2.2 Left-sided valvular heart disease</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.1 Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.2 Intersitial lung disease</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.3 O sleep-disordered breathing</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.4 Alveolar hypoventilation disorders</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.5 Chronic exposure to high altitude</td>
</tr>
<tr>
<td>3. PH associated with lung disease and/or hypoxemia</td>
<td>3.6 Development abnormalities</td>
</tr>
<tr>
<td>4. PH due to chronic thrombotic and/or embolic disease</td>
<td>4.1 Thromboembolic obstruction of proximal pulmonary arteries</td>
</tr>
<tr>
<td>4. PH due to chronic thrombotic and/or embolic disease</td>
<td>4.2 Thromboembolic obstruction of distal pulmonary arteries</td>
</tr>
<tr>
<td>4. PH due to chronic thrombotic and/or embolic disease</td>
<td>4.3 Non-thrombotic pulmonary embolism (tumor, parasites, foreign material)</td>
</tr>
<tr>
<td>5. Miscellaneous</td>
<td>Sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangiomatosis, compression of pulmonary vessels by adenopathy, tumor fibrosing mediastinitis, or other process</td>
</tr>
</tbody>
</table>

vasodilation resulting in hypotension, headache and jaw pain, or hypoxemia due to ventilation/perfusion (V/Q) mismatch, or right to left shunting (Rubin 1997; Castro et al 1998). Other potential adverse effects include infections, thrombosis, and malfunction of the delivery system resulting in pulmonary hypertensive crisis (Barst et al 1996).

Two randomized trials have shown significant improvements in 6 minute walk distance, hemodynamics, and time to clinical worsening during treatment with the oral endothelin A/B receptor antagonist bosentan (Channick et al 2001; Rubin et al 2002). The most common adverse effect is a dose-related elevation in liver enzymes that can occur in up to 11% of patients and necessitate cessation of therapy (Lee and Channick 2005).

Pharmacology and acute effects of sildenafil in PH

Sildenafil is a selective and potent inhibitor of PDE type 5 which specifically degrades cyclic guanosine monophosphate and is found in high concentrations in pulmonary arteries and the corpora cavernosum (Rabe et al 1994; Ahn et al 1991; Boolell et al 1996; Pauvert et al 2002; Pauvert et al 2003). Normally, endothelium-derived NO stimulates intracellular soluble guanylate cyclase resulting in increased levels of cGMP, which then acts to mediate smooth muscle relaxation (Figure 1). Sildenafil inhibits the degradation of cGMP by PDE 5 and prolongs the actions of cGMP.

Metabolism of sildenafil occurs primarily by hepatic cytochrome P450 enzymes yielding one active metabolite with a potency of approximately 50% of the parent drug. Patients with age greater than 65, with creatinine clearance less than 30, and with hepatic cirrhosis have reduced clearance of sildenafil.

During trials for erectile dysfunction, sildenafil was administered to more than 3700 patients worldwide with over 550 patients treated for more than one year. Adverse events included headache 16%, flushing 10%, dyspepsia

Figure 1 Mechanism of vasodilatory and antiproliferative effects of sildenafil. NO from vascular endothelial cells stimulates the activity of sGC which produces cGMP from GTP. Sildenafil inhibits the breakdown of cGMP to GMP by PDE 5, increasing cellular concentrations of cGMP which increases the formation of PKG. Competitive inhibition of PDE inhibits breakdown of cAMP which stimulates increased production of PKA. Vasodilation results primarily from modulation of ion channel activity by cGMP with a lesser contribution from increased levels of cAMP. Inhibition of smooth muscle cell proliferation occurs via increased levels of PKA and PKG.

Abbreviations: AMP, adenosine monophosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; GMP, guanosine monophosphate; GTP, guanosine triphosphate; NO, nitric oxide; PDE 5, phosphodiesterase type 5; PKA, cAMP dependent protein kinase; PKG, cGMP dependent protein kinase; sGC, soluble guanylate cyclase.
7%, and nasal congestion 4% and were similar to those reported in the largest trial of sildenafil in PAH (Galiè et al 2005). Sildenafil leads to a small, usually clinically insignificant drop in blood pressure (Kloner 2004). Cases of vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION) have been reported (McGwin et al 2006), but have not occurred during studies of pulmonary hypertension (Galiè et al 2005; Machado et al 2005). Inhibition of the hepatic P450 enzyme system can potentiate adverse effects of sildenafil by accelerating or decreasing its metabolism and clearance.

Trials of sildenafil to date have exploited its ability to cause rapid and potent vasodilation resulting in improved hemodynamics. Acute administration of a single oral dose of sildenafil causes a significant decrease in mPAP and PVR with minimal or no affect on mean arterial pressure (MAP) and improvement, or a trend towards improvement, in cardiac output. The effect peaks at 60 minutes and lasts as long as 4 hours (Hoepner et al 2000; Ghofrani et al 2002a, 2002b; Lepore et al 2002; Michelakis et al 2002). Two studies found a dose-dependent relationship for changes in cardiac index (CI), pulmonary arterial pressure, and pulmonary vascular resistance index (PVRI) (Ghofrani et al 2002a, 2002b). One report describes a decrease in the ratio of PVR to systemic vascular resistance (SVR) at lower doses, suggesting selectivity for the pulmonary vasculature (Ghofrani et al 2002a). The magnitude of the effect in the pulmonary circulation is comparable to that of inhaled NO, iloprost, and prostacyclin (Hoepner et al 2000; Lepore et al 2002).

Vasodilators may improve hemodynamics, but treatments that inhibit or reverse vascular remodeling to slow inevitable disease progression are being sought. Sildenafil may prevent or reverse remodeling through NO and cGMP modulation of smooth muscle proliferation and apoptosis (Figure 1) (Garg and Hassid 1990; Lee et al 1996; Pollman et al 1996; Chiche et al 1998; Osinski et al 2001). Clinical data with adequate follow-up time in patients treated with sildenafil are so far inadequate to address this possibility, but limited data from early studies suggest that it is plausible and mechanistically sound.

In one report, sildenafil inhibited platelet derived growth factor (PDGF)-induced DNA synthesis and cell proliferation, and inhibited hypoxia-induced cell proliferation. Increased levels of cGMP indirectly lead to increased levels of cAMP which may suppress transcription of DNA, activate anti-proliferative protein kinases, and inhibit PDGF activity (Tantini et al 2005). In vivo, sildenafil has been shown to prevent and reverse remodeling in monocrotaline-, hypoxia-, and overcirculation-induced animal models of PAH (Sebkhi et al 2003; Itoh et al 2004; Rondelet et al 2004; Schermuly et al 2004). In humans, PDE 5 expression was increased in remodeled pulmonary arteries from patients with idiopathic PAH and familial PAH. Stimulation of the cGMP pathway inhibited DNA synthesis and cell proliferation and promoted apoptosis in isolated pulmonary artery smooth muscle cells, an effect potentiated by sildenafil (Wharton et al 2005).

**Clinical applications**

The use of sildenafil to treat PH from a variety of causes has increased dramatically although, for many applications, only case reports or small series offer evidence of safety and efficacy. Future large, well designed trials are critical to direct physicians in the treatment of unstudied populations who might benefit from sildenafil.

**PAH**

Three randomized controlled trials have been performed to evaluate the use of sildenafil in patients with PAH (Table 2). Ten patients with New York Heart Association (NYHA) classification ≥2, pulmonary artery systolic pressure (PASP) ≥35 mmHg, normal left ventricular function, and no reversible cause of PAH were included in a prospective randomized, placebo-controlled cross over study to evaluate the effects of short-term sildenafil treatment. PAH was idiopathic (3), or related to interstitial lung disease (2), chronic thromboembolic disease (1), or chronic left to right shunt (3). Patients in the sildenafil group had an improvement in the primary endpoint of 6 minute walk distance from 163.9 to 266.7 m (p<0.005) compared with no change with placebo. Changes in secondary endpoints with sildenafil treatment included a decrease in the Borg dyspnea index and PASP from 5.2 to 3.6 (p<0.01) and 80.8 to 55.3 mmHg (p<0.05) respectively (Bharani et al 2003).

In another trial, 22 patients with NYHA class II-III and PASP >70 mmHg by echocardiography were randomized to 6 weeks of sildenafil or placebo with subsequent crossover. The primary endpoint of exercise time decreased non-significantly compared with baseline in the placebo first group, but increased from 451 to 698 seconds during sildenafil (p<0.001) then decreased to 527 seconds during placebo (p<0.001 compared with baseline) in the sildenafil first group. When the groups were combined, exercise time increased from 475 seconds after placebo to 686 seconds after 6 weeks of sildenafil (p<0.0001). Cardiac index (2.8–
Sildenafil in PH

2.45 L min⁻¹ m⁻², p<0.0001) and quality of life measures for dyspnea and fatigue improved although there was no significant difference in PASP (Sastry et al 2004).

The Super-1 trial was an international multicenter, randomized, blinded, controlled study involving 278 patients with symptomatic PAH that was idiopathic, associated with connective tissue disease, or repaired congenital systemic to pulmonary shunts. Patients were stratified according to baseline walk distance and etiology of PAH and randomized to placebo or sildenafil at a dose of 20, 40, or 80 mg 3 times daily for 12 weeks followed by a long-term extension study of sildenafil 80 mg. For the primary outcome of exercise capacity, there was a significant improvement in 6 minute walk distance in all patients taking sildenafil (Table 3). There was no significant difference in time to clinical worsening, but fewer patients taking sildenafil were hospitalized for worsening PAH. One patient developed left ventricular dysfunction and one patient had postural hypotension thought to be related to sildenafil (Galiè et al 2005). There was a non-significant trend towards improved hemodynamics with higher doses and the extension study showed favorable results of long-term treatment with 80 mg.

The only comparative treatment trial studied patients with idiopathic or collagen vascular disease associated PAH who were symptomatic despite maximal conventional therapy. For the primary outcome of right ventricular mass, there was a significant improvement in baseline versus sildenafil but no difference between baseline and bosentan or between sildenafil and bosentan. There were differences between treatment groups (sildenafil superior) only in 6

### Table 2 Summary of randomized controlled trials of sildenafil in the treatment of PAH (Bharani et al 2003; Sastry et al 2004; Galiè et al 2005)

<table>
<thead>
<tr>
<th></th>
<th>Bharani 2003</th>
<th>Sastry 2004</th>
<th>Galiè 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial design</td>
<td>Randomized, placebo controlled, double blind, crossover</td>
<td>Randomized, placebo controlled, double blind, crossover</td>
<td>Randomized double blind, placebo controlled</td>
</tr>
<tr>
<td>No (male)</td>
<td>9 (4)</td>
<td>22 (10)</td>
<td>277 (68)</td>
</tr>
<tr>
<td>Etiology (number)</td>
<td>Idiopathic PAH (3)</td>
<td>Idiopathic PAH (22)</td>
<td>Idiopathic PAH (175) CTD (84)</td>
</tr>
<tr>
<td></td>
<td>Left to right shunt (3)</td>
<td></td>
<td>Left to right shunt (18)</td>
</tr>
<tr>
<td></td>
<td>Thromboembolism (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ILD (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration</td>
<td>2 weeks</td>
<td>6 weeks</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Primary outcome</td>
<td>6 min walk 170 m at end of placebo phase vs 266 m at end of sildenafil phase, p&lt;0.005</td>
<td>Exercise treadmill time 475±168 s at end of placebo phase vs 686±224 s at end of sildenafil phase, p&lt;0.0001</td>
<td>Placebo corrected increase in mean 6 min walk distance 20, 40, and 80 mg; 45, 46, and 50 m (p&lt;0.001)</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td>Significant improvement in Borg dyspnea score and PASP</td>
<td>Significant improvement in cardiac index and QOL, no change in PASP</td>
<td>Significant improvement in mPAP, CI (40 and 80 mg dose), PVR, WHO functional class, no change in time to worsening or Borg dyspnea scale Increased rate of headache and epistaxis in sildenafil group</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>None reported</td>
<td>Similar to placebo</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3 Results of the Super-1 trial showing improvements in hemodynamics and 6 minute walk test with use of sildenafil

<table>
<thead>
<tr>
<th>Effect at 8 weeks</th>
<th>Placebo (95% confidence interval)</th>
<th>20 mg (95% confidence interval)</th>
<th>40 mg (95% confidence interval)</th>
<th>80 mg (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 minute walk distance (placebo corrected, in meters)</td>
<td>45 (21, 70)</td>
<td>46 (20, 72)</td>
<td>50 (23, 77)</td>
<td></td>
</tr>
<tr>
<td>Mean pulmonary artery pressure (mmHG)</td>
<td>0.6 (−0.8, 2.0)</td>
<td>−2.1 (−4.3, 0.0)</td>
<td>−2.6 (−4.4, −0.9)</td>
<td>−4.7 (−6.7, −2.8)</td>
</tr>
<tr>
<td>Cardiac index (L min⁻¹ m⁻²)</td>
<td>−0.02 (−0.17, 0.13)</td>
<td>0.21 (0.04, 0.8)</td>
<td>0.24 (0.05, 0.42)</td>
<td>0.37 (0.20, 0.55)</td>
</tr>
<tr>
<td>PVR (dynes s⁻¹ cm⁻⁵)</td>
<td>49 (−54, 153)</td>
<td>−22 (−217, −27)</td>
<td>−143 (−218, −69)</td>
<td>−261 (−365, −157)</td>
</tr>
</tbody>
</table>

### Abbreviations:
CTD, connective tissue disease; ILD, interstitial lung disease; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance; QOL, quality of life.
minute walk distance and quality of life score (Wilkins et al 2005).

The Super-1 trial is the only high quality, randomized, blinded controlled study that has shown a benefit of treatment with sildenafil. The study population was made up largely of individuals with idiopathic PAH, and subgroup analysis of patients with other diagnoses failed to show a statistically significant improvement in 6 minute walk distance at a dose of 20 mg 3 times daily. Some experts have expressed concern that FDA approval of only the 20-mg dose could result in some patients being harmed by undertreatment (Hoeper et al 2006). For now, data are adequate to support treatment of PAH with sildenafil. Although accumulating evidence is encouraging and reported toxicities are limited, sildenafil treatment for PH other than PAH should be considered experimental.

HIV-associated PAH
HIV-associated PAH is estimated to occur in 0.5% of infected patients with a mortality approaching 50% at 36 months (Speich et al 1991; Pellicelli et al 2001). Pathologic examination shows plexiform lesions and the disease is thought to be mediated by endothelial dysfunction secondary to the host immune response or HIV therapy. Calcium channel blocker therapy is not successful and patients are particularly susceptible to adverse effects of prostacyclin infusion and to bosentan associated hepatic toxicity. Treatment of HIV-associated PAH with sildenafil has been limited due to interactions between sildenafil and protease inhibitors and recreational use of street drugs such as amyl nitrate. Successful treatment with sildenafil has been reported in 3 adult patients with HIV-associated PAH (Schumacher et al 2001; Carlsen et al 2002; Alp et al 2003). All three patients showed improvements in hemodynamics, functional class, and symptoms. Treatment of one 18-month-old patient with super systemic pulmonary artery pressures and right heart dysfunction has also been reported. Twelve months of sildenafil resulted in near resolution of right heart abnormalities by echocardiography (Wong et al 2006).

Hemolysis associated PAH
PAH affects approximately 30% of patients with sickle cell anemia (Sutton et al 1994; Castro 1996; Castro et al 2003; Castro and Gladwin 2005) and has been identified as a major independent predictor of death (Gladwin et al 2004). A hemolysis-mediated decrease in NO bioavailability (Reiter et al 2002) increased production of endothelin-1 and free radicals, platelet activation, and endothelial dysfunction along with chronic hypoxia, and a prothrombotic state occurs in hemolytic disorders resulting in PAH (Machado and Gladwin 2005). Because of the abnormally high rate of NO destruction central to the pathophysiology of these disorders, sildenafil may be a uniquely well suited treatment choice.

One small study evaluated the efficacy and safety of sildenafil in 7 patients with thalassemia intermedia, thalassemia major, and sickle cell thalassemia with advanced disease despite maximal conventional therapy. All patients experience progressive hemodynamic and symptomatic improvement. No patients reported adverse effects and no patients stopped the drug due to adverse effects (Derchi et al 2005).

In another small, uncontrolled, open label trial we evaluated the effects of sildenafil on hemodynamics and functional status in patients with mild to moderate PAH and impaired exercise capacity associated with sickle cell disease. Acute administration of sildenafil during right heart catheterization resulted in a statistically significant change of mPAP of –26%, PVR of –57%, CI of 45%, and PVR to SVR ratio of –38%, suggesting preferential pulmonary vasodilation. Among 12 patients treated chronically, pulmonary artery systolic pressure (PASP) measured by echocardiogram and 6 minute walk improved significantly from 50 to 41 mmHg and 384 to 462 m respectively. One patient had to stop treatment due to headaches (Machado et al 2005). Based on these results, a large National Heart Lung and Blood Institute sponsored randomized trial of sildenafil in sickle cell anemia-associated PAH will be launched in the next 12 months.

Portopulmonary hypertension
Pulmonary hypertension with a mPAP of 40–45 mmHg prior to liver transplantation is associated with a mortality of 70%–80% (Makisalo et al 2004) and successful treatment of PH is required prior to listing for transplant. End stage liver disease precludes the use of bosentan and prostacyclin use is especially challenging in this population. However, concerns have been raised about the interaction of the potential antiplatelet effect of sildenafil and bleeding diathesis that results from liver disease.

The literature contains reports of 2 patients with primary biliary cirrhosis hepatitis C complicated by portopulmonary hypertension who were treated with sildenafil. Both patients responded well allowing liver transplantation to proceed. One patient developed a hematoma post-operatively that may have been secondary to the antiplatelet effects of sildenafil (Makisalo et al 2004; Chua et al 2005). Another
small trial studied 14 patients with portopulmonary hypertension treated with sildenafil or inhaled iloprost plus sildenafil. Patients had a statistically significant improvement in PVR and 6 minute walk distance at 3 and 12 months follow up. Two patients died as a result of their underlying disease but there were no adverse bleeding events related to sildenafil (Reichenberger et al 2006).

**Persistent PH of the newborn**

Persistent PH of the newborn (PPHN) occurs when PVR remains elevated after birth resulting in right to left shunting and hypoxemia. The incidence is 0.43–6.8/1000 live births and it has a mortality rate of 10%–20% (Travadi and Patole 2003). Management is supportive and inhaled NO and extra corporeal membrane oxygenation (ECMO) are indicated if they are available (Schreiber et al 2003). Sildenafil could provide a feasible and cost-effective alternative to inhaled NO and ECMO (Kumar 2002). Three cases of children between 7 days and 5 months of age with bronchopulmonary dysplasia, an intracardiac shunt, and acute respiratory failure treated with sildenafil have been published. All patients were critically ill, requiring maximal available hemodynamic and respiratory support. After beginning sildenafil, all patients had rapid improvement (Chaudhari et al 2005; Hon et al 2005; Juliana and Abbad 2005).

**Pediatric patients with PAH**

One open label single drug trial evaluated the effects of 12 months of sildenafil-treatment pediatric patients with idiopathic PAH, post op congenital heart defect repair, and Eisenmenger syndrome. Right heart catheterization in 9 showed a significant reduction in mPAP from 60 to 50 mmHg and a decrease in pulmonary vascular resistance index from 15 to 12 wood units/m² without a change in systemic hemodynamics. Six minute walk distance increased from a mean of 278 m to 432 m. There were no deaths during the 12-month study period compared with 37% survival in historical controls (Humpl et al 2005).

**Combination therapy in PAH**

Data on combination therapy in PH is limited, but it has already become common practice among some physicians (Hoeper and Dinh-Xuan 2004). Similar to therapy of congestive heart failure, patients may benefit from synergistic effects of drugs with disparate mechanisms of action. Numerous small trials have begun exploring the utility of this approach.

In one study, exercise treadmill time, dyspnea fatigue score, and WHO functional class improved in 8 patients on chronic, subcutaneous treprostenol treated with oral sildenafil (Gomberg-Maitland et al 2005). Another study examined 30 patients with idiopathic PAH, CREST, congenital vascular defect, or chronic thromboembolic disease treated with inhaled NO followed by inhaled iloprost then by sildenafil alone or inhaled iloprost plus sildenafil. With combined iloprost and sildenafil therapy, the effect on mPAP, PVR, and CI was more pronounced and longer lasting, and the vasodilatory response was greater than for the sum of the individual therapies, suggesting treatment synergy (Ghofrani et al 2002). Ghofrani and colleagues also studied 14 patients deteriorating on inhaled iloprost and found that the addition of sildenafil resulted in an increased 6 minute walk distance, decreased mPAP, decreased PVR, and improved functional class (Ghofrani et al 2003). Lastly, a study of beraprost and sildenafil resulted in a more potent lowering of the mPAP and a longer treatment effect than beraprost alone (Ikeda et al 2005).

A study of goal-based therapy versus historical controls treated with inhaled or i.v. prostaglandins involved treatment with bosentan followed by the addition of sildenafil, inhaled iloprost, or change to intravenous iloprost, to achieve a 6 minute walk distance >380 m, a peak oxygen uptake >10.4 mL·min⁻¹·kg⁻¹ and a peak SBP during exercise of >120 mmHg. Among 123 patients enrolled, 43.2% met treatment goals on 2 drugs, 16.1% on 3, and 4.2% required intravenous iloprost. Mortality (23.8% vs 13.8%) and transplantation-free survival were better in the goal based treatment group (Hoeper et al 2005).

**PH**

Heart failure, cardiac surgery, and cardiac transplant

Pulmonary hypertension is a complication of heart failure from left ventricular dysfunction associated with increased mortality and is a contraindication to heart transplant (Erickson et al 1990; Costard-Jackle and Fowler 1992; Delgado et al 2001). Sildenafil has been used in the pre-operative period in 2 studies to test vasoreactivity (Alaeddini et al 2004) and to successfully treat established PH that would have otherwise been a contraindication to heart transplant (Gómez-Moreno et al 2005).

PH can also complicate cardiac and peripheral vascular surgery and is thought to be due to pulmonary endothelial dysfunction related to cardiopulmonary bypass and other
factors (Hayward et al 1999; Fung et al 2005). Standard therapies include beta agonists, PDE III inhibitors, and intravenous or inhaled nitrovasodilators (Trachte et al 2005). Treatment with sildenafil, however, is growing more common even in the absence trial data to support its use (Madden and Crerar-Gilbert 2005).

Three reports describe the use of sildenafil for worsening PH in post-operative patients requiring multiple pressors and inotropic support. In one, sildenafil decreased the mPAP from 58 to 29 mmHg and the PCWP from 32 to 18 mmHg after coronary bypass and mitral annuloplasty, improving systemic blood pressure. In the second, sildenafil was given intra-operatively during an aortic valve replacement for a mPAP of 90 mmHg accompanied by systemic hypotension despite epinephrine, milrinone resulting in a decrease in mPAP to 50 mmHg (Madden and Crerar-Gilbert 2005). In a third, patients’ status post mitral valve surgery or left ventricular assist device (LVAD) placement who received sildenafil for elevated PAP had significant improvement in MAP, mPAP, and PVRI. SVRI decreased, but the PVR/SVR ratio decreased consistent with a preferential pulmonary vasodilation (Trachte et al 2005).

PH is common in the peri-operative period in pediatric cardiac surgery and may respond to treatment with sildenafil. In 12 children with an increased PVRI after cardiac surgery, sildenafil resulted in a significant decrease in PVRI that was greater than that achieved with NO alone, and PVRI/SVRI ratio was consistent with pulmonary selectivity. The addition of NO to sildenafil did not result in a greater benefit. A significant increase in shunt fraction from 16.5% to 25.5% occurred after treatment with sildenafil; however, no patients experienced hypoxia and dead space ventilation remained unchanged. The authors concluded that treatment with inhaled NO and sildenafil were equivalent (Schulze-Neick et al 2003).

A prospective study randomized 15 ventilated infants after ventricular or atrial septal defect closure to receive NO followed by sildenafil or the same therapies in the reverse order. Although sildenafil treatment decreased mPAP and PVRI, the study was stopped early due to worsening oxygenation and systemic hypotension associated with sildenafil (Stocker et al 2003).

Pulmonary thromboembolic disease
Sildenafil has been used in a case of acute pulmonary embolism and right heart failure in the setting of chronic PAH from right to left shunt. A 58-year-old woman hospitalized with a massive tri-lobe pulmonary embolism was found to have a PASP of 100 mmHg accompanied by severe refractory hypoxemia. Sildenafil was started and after 2 hours, PVRI had decreased from 700 to 425 dyne·s⁻¹·cm⁻⁵·m⁻² and CI had increased from 2.1 to 3.2 L·min⁻¹·m⁻² with no change in mPAP (Ganiere et al 2006).

The effects of sildenafil were studied in 12 patients with severe chronic thromboembolic PH (CTEPH) who were not candidates for thrombectomy. Average baseline mPAP, PVRI, and CI were 52.6 mmHg, 1935 dyne·s⁻¹·cm⁻⁵·m⁻² and 2.01 min⁻¹·m⁻². After approximately 6.5 months of sildenafil treatment, a statistically significant improvement had occurred in all parameters with a mPAP, PVRI, and CI of 44.9 mmHg, 1361 dyne·s⁻¹·cm⁻⁵·m⁻², and 2.4 min⁻¹·m⁻², respectively, and no adverse events (Ghofrani et al 2003b).

Pulmonary fibrosis associated PH
Fibrotic lung disease is frequently associated with PH and can be a source of significant morbidity and mortality (King et al 2001). In patients with interstitial lung disease, systemic administration of vasodilators can increase blood flow to poorly ventilated areas overriding physiologic hypoxic vasoconstriction, leading to worsening V/Q mismatch and shunting with a resultant decrease in arterial oxygenation. Nebulized or inhaled therapies avoid this problem by distributing preferentially to well ventilated alveoli, but delivery systems can be costly and cumbersome to use.

A randomized, open label trial examined the effects of acute administration of oral sildenafil on V/Q matching in interstitial lung disease. Sixteen patients with fibrotic lung disease (idiopathic pulmonary fibrosis, CREST, systemic sclerosis, silicosis, and extrinsic allergic alveolitis) and an mPAP greater than 35 mmHg underwent vasodilator testing with inhaled NO and were randomized to receive intravenous epoprostenol or oral sildenafil. Inhaled NO, epoprostenol, and sildenafil all resulted in a significant decrease in mPAP and PVRI. Cardiac output remained nearly constant in the NO group, while it increased in the sildenafil group and increased to a greater extent in the epoprostenol group. Inhaled NO caused a non-significant decrease in pulmonary shunt flow and a moderate increase in the partial pressure of oxygen. Epoprostenol resulted in a large, significant 16.8% increase in shunt flow, a decrease in the PaO₂, increased perfusion to low V/Q areas, and an increase in mean ventilation. Oral sildenafil resulted in a non-significant decrease in shunt flow and a rise in the partial pressure of oxygen. The authors concluded that sildenafil
induces vasodilation selectively in well ventilated lung units by acting through intrinsic vasodilator/vasoconstrictor pathways (Ghofrani et al 2002c). There are, however, no data evaluating the chronic effects of sildenafil on PH related to alveolar hypoxemia.

Altitude-associated PH

High altitude pulmonary edema (HAPE) is a syndrome that occurs shortly after ascent due to a deranged response to hypoxia and hypobaria in susceptible individuals and accounts for the majority of deaths related to high altitude (Schäfer and Bauersachs 2002). The mechanism is unclear but may be related to an abnormally pronounced degree of pulmonary vasoconstriction secondary to abnormalities in vasodilators and vasoconstrictors (such as NO and endothelin-1), pulmonary capillary tears and leaks, exaggerated sympathetic tone, and induction and release of inflammatory cytokines (Basnyat and Murdoch 2003).

Treatment with portable hyperbaric chambers, supplemental oxygen, and nifedipine have been studied in small trials, but their utility is limited by availability and adverse effects. Several trials have examined the role of sildenafil in attenuating the effects of alveolar hypoxia on pulmonary artery pressures and in improving exercise tolerance.

Ghofrani et al examined the response of exercise pulmonary hemodynamics to sildenafil during hypoxic conditions at sea level and at the Mount Everest base camp. When compared with baseline, all participants had a significant pulmonary hypertensive response to hypoxic conditions at sea level and at Everest base camp. The effect was augmented by exercise but significantly blunted by treatment with a one time dose of 50mg of sildenafil (increase in mPAP: placebo group sea level hypoxia rest +75%, exercise +145%; Everest rest +57%, exercise +92%; sildenafil sea level hypoxia rest +26%, exercise +108%; Everest rest +26%, exercise +57%). Sildenafil treatment also resulted in a statistically significant improvement in exercise tolerance under hypoxic or high altitude conditions (hypoxic exercise +20%, Everest exercise +11%) without affecting systemic blood pressure, heart rate, or oxygen saturation (Ghofrani et al 2004).

Another trial examined the effects of sildenafil on hemodynamics in 12 healthy men at sea level, and at 4350m before and after treatment with sildenafil. The sildenafil group had a significantly lower heart rate, higher oxygen saturation, and lower PASP compared with the placebo group. During exercise testing, peak oxygen consumption was higher in the sildenafil group than the placebo group (Richalet et al 2005).

Chronic mountain sickness is a syndrome occurring with long-term exposure to altitude that can result in PH and right heart failure (Ge and Helun 2001). A randomized, controlled study evaluated the use of sildenafil to treat PH in residents of the Naryn region of Kyrgyzstan, 2500–4000 m a.s.l. Twenty-two patients with PH were randomized to treatment with a single dose and then chronic administration of placebo versus 25 or 100 mg of sildenafil every 8 hours. Compared with placebo, there was a significant decrease in mPAP of 6.7 and 11.6 mmHg after the first dose of sildenafil and at 12 weeks, respectively. Six minute walk and physical symptoms score improved significantly by 43.5 m and 10.4 points at 12 weeks compared with placebo. There was a trend towards a decrease in PVR in the treatment groups (Aldashev et al 2005).

Conclusion

Over the last two decades, enormous progress has been made in the treatment of patients with PH resulting in significant improvement in morbidity and mortality. One example of such advances was the advent of oral therapies for PAH. In this context, sildenafil has emerged as an effective first-line oral therapeutic agent for patients with symptomatic PAH who do not have indications for treatment with intravenous prostacyclin. Salutary effects that may play an important role in the clinical efficacy of sildenafil, but require further study include selective pulmonary vasodilation and antiremodeling properties. Sildenafil shows promise as a useful therapy in numerous case reports of PH from a variety of causes. With the exception of post-operative pediatric cardiac surgery patients, sildenafil has not been associated with significant adverse effects in any of the subtypes of PH for which it has been studied. Clarification of the role of sildenafil in forms of PH other than idiopathic PAH will require future well designed trials.

Disclosures

The authors have no conflicts of interest to declare.

References


